Notice of Proposed Sale · 144
Verastem, Inc.
VSTMNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Verastem, Inc.
- Issuer CIK
- 0001526119
- SEC file number
- 001-35403
- Phone
- 781-292-4200
- Person for whose account securities are to be sold
- Dan Paterson
- Relationships to issuer
- Officer, Director
- Street
- 117 Kendrick Street, Suite 500
- City
- Needham
- State / country code
- MA
- Postal code
- 02494
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 44,121 | 353,047.00 | 90,563,441 | 10/01/2026 | NASDAQ | Shareworks by Morgan Stanley |
Broker / market maker — proposed row 1, entry 1
- Name
- Shareworks by Morgan Stanley
- Street
- 600 - 3 Avenue SW
- Street (continued)
- Suite 1500
- City
- Calgary
- State / country code
- A0
- Postal code
- T2P0G5
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 01/21/2026 | Vesting of restricted stock unit award | Verastem, Inc. | 44,121 | N | 01/21/2026 | N/A |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| Dan Paterson | Verastem, Inc. | 08/03/2026 | 1,302 | 7,565.00 |
Seller — prior-sale row 1, entry 1
- Name
- Dan Paterson
- Street
- 117 Kendrick Street
- Street (continued)
- Suite 500
- City
- Needham
- State / country code
- MA
- Postal code
- 02494
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Remarks
Shares to be sold to cover withholding taxes upon vesting of restricted stock unit awards
Notice signature
- Notice date
- 10/01/2026
- Signed
- /s/ Daniel Calkins, attorney-in-fact
- Plan adoption dates
- 10/01/2026
Company context
Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI® FAKZYNJA® CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.
Current securities
Recent company filings
- SCHEDULE 13G/A - filed by ARMISTICE CAPITAL, LLC regarding Verastem, Inc.Aug 14, 2026
- Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Regulation FD DisclosureAug 7, 2026
- Results of Operations and Financial ConditionAug 6, 2026
- 10-Q filingAug 6, 2026
- SCHEDULE 13G filingJul 31, 2026